+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Imfinzi

  • ID: 4462230
  • Drug Pipelines
  • 47 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells. By inhibiting the PD-1/PD-L1 interaction, Imfinzi reduces the ability of the tumor to evade immune system targeting and enables the activation of T cells and the adaptive immune system.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Imfinzi : Non-small cell lung cancer (NSCLC)
Imfinzi : Head and neck cancer
Imfinzi : Bladder cancer

LIST OF FIGURES
Figure 17: The authors drug assessment summary for Alunbrig in non-small cell lung cancer
Figure 22: Cyramza for non-small cell lung cancer – SWOT analysis
Figure 18: Avastin for non-small cell lung cancer – SWOT analysis
Figure 23: The authors drug assessment summary for Cyramza in non-small cell lung cancer
Figure 20: Avastin sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 21: The authors drug assessment summary for Bavencio in non-small cell lung cancer
Figure 27: The authors drug assessment summary for Gilotrif in non-small cell lung cancer
Figure 28: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Imfinzi drug profile
Table 2: Imfinzi pivotal trial data in non-small cell lung cancer
Table 3: Imfinzi late-phase trial data in non-small cell lung cancer
Table 4: Imfinzi ongoing late-phase clinical trials in non-small cell lung cancer
Table 5: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Imfinzi patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 7: Imfinzi drug profile
Table 8: Imfinzi Phase III trials in head and neck cancer
Table 9: Imfinzi early-phase data in head and neck cancer
Table 10: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 11: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 12: Imfinzi drug profile
Table 106: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll